富亮氨酸 α‑2‑糖蛋白 1(LRG1)是一种多功能血浆蛋白,健康人体内其浓度为 21‑50 μg/mL。作为急性期反应蛋白,LRG1 水平在细菌感染及多种炎症状态下会显著升高,但其调控机制独立于 C 反应蛋白(CRP)等传统标志物。LRG1 在调控免疫与血管应答中发挥关键作用,是 TGF‑β 信号通路的上游调节因子,并可通过影响内皮细胞行为促进血管生成。它能够结合凋亡相关分子细胞色素 c,由此可能在组织损伤和炎症过程中助力细胞存活。
常见研究用途
LRG1 升高被公认为多种癌症的生物标志物,包括非小细胞肺癌、结直肠癌、胰腺癌以及卵巢癌,其表达水平与疾病进展及预后具有相关性。除肿瘤领域外,LRG1 还参与心血管疾病、肾脏疾病、自身免疫病以及帕金森病等神经退行性疾病的病理过程;鉴于其在炎症、血管功能紊乱和组织重塑中的作用,目前正被开发为诊断标志物与治疗靶点。
常见应用:体外诊断(IVD)检测标准品、校准品与质控品;治疗药物研究;免疫系统研究。
供体原料由完成全套传染病筛查的供应商提供。原料采集前已完成检测,HIV、HBV、HCV 及梅毒均为阴性。
Leucine-rich alpha-2 glycoprotein 1 (LRG1) is a multifunctional plasma protein present at concentrations of 21–50 μg/mL in healthy individuals. As an acute-phase protein, LRG1 levels rise significantly during bacterial infections and various inflammatory conditions, but its regulation is independent of traditional markers like C-reactive protein (CRP). LRG1 plays a key role in modulating immune and vascular responses, acting as an upstream regulator of the TGF-β signaling pathway and promoting angiogenesis by influencing endothelial cell behavior. It binds cytochrome c, a molecule involved in apoptosis, thereby potentially supporting cell survival during tissue injury and inflammation.
Common research uses
Elevated LRG1 is recognized as a biomarker for multiple cancers-including non-small cell lung, colorectal, pancreatic, and ovarian cancer-where it correlates with disease progression and prognosis. Beyond oncology, LRG1 is implicated in cardiovascular, renal, autoimmune, and neurodegenerative diseases, such as Parkinson’s disease, and is being explored as a diagnostic and therapeutic target due to its roles in inflammation, vascular dysfunction, and tissue remodeling.
Common uses include IVD Assay standards, calibrators and controls, therapeutics research, immune system research.
Donor material is obtained from suppliers that perform a comprehensive infectious disease screening panel. This material was tested and found negative for HIV, HBV, HCV, and syphilis prior to collection.